Semaglutide Weight Management and Cardiovascular Risk Reduction

Mean HbA1c reduction from baseline was -2.18 %-points and 89% reached HbA1c target when treated with CagriSema Higher HbA1c reduction with CagriSema compared to monocomponents Mean baseline HbA1c 8.4% Achievement of HbA1c target <7.0% after 32 weeks Change in HbA1c (%-points) 0.0 -1.0 -2.0 -3.0 0 4 812 20 20 Time since randomisation (weeks) CagriSema Semaglutide Cagrilintide -0.93 -1.79 -2.18 28 32 100 89% 00 80 % of patients Note: Data shown is trial product estimands. CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mg 60 60 40 40 20 20 69% 33% CagriSema Semaglutide Cagrilintide More participants achieved the HbA1c target when treated with CagriSema compared to the monocomponents

View entire presentation